… Drug makers are exploring radioligand therapies, gene-based treatments, and vaccine- … December: The FDA approved AKEEGA (niraparib and abiraterone acetate) as the … Prostate Cancer Treatment Market is undergoing a crucial transformation driven by medical …

… trial of Rubraca® (rucaparib) in chemotherapy-naïve metastatic castration-resistant prostate cancer … of docetaxel, abiraterone acetate, or … treatment resistance.7 Rubraca® (rucaparib) U.S. Prostate Cancer FDA … of specialty pharmaceuticals across multiple …

… associated metastatic castration-resistant prostate cancer (mCRPC) previously treated … will be posted on Drugs@FDA.  Safety and Efficacy … received (enzalutamide or abiraterone acetate) or docetaxel. … of testosterone via treatment with androgen deprivation …

… metastatic castration-sensitive prostate cancer, with particular attention to treatment intensification, selection among … tolerate chemotherapy, provided that clinicians remain attentive to adverse events and drug …

… prostate cancer (mCSPC). The conversation centered on treatment … Xtandi), apalutamide (Erleada), abiraterone acetate (Zytiga), and darolutamide … , cardiovascular health, medication burden, and patient … therapy and chemotherapy considerations The conversation …

… , Patel focuses on treatment intensification, post-prostatectomy management … abiraterone acetate (Zytiga)—for very high-risk localized prostate cancer. … closer collaboration with medical oncology and more … setting, where recent trials have reshaped the …

… in the chemotherapy-naïve castration- … TRITON3 trial (NCT02975934), in which treatment with … enzalutamide [Xtandi] or abiraterone acetate) or docetaxel … drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer 2. FDA …

… treatments to slow progression, manage symptoms, and extend survival. In the trial … enzalutamide, abiraterone acetate, or … drugs/;resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer …

… chemotherapy. It is also approved for the treatment … Pharma, Pfizer], abiraterone acetate [Zytiga; Janssen Biotech]), or docetaxel … control medications.5 Additionally, the FDA states … Metastatic Castration-resistant Prostate Cancer and Homologous Recombination …

… FDA has granted regular approval to rucaparib (Rubraca) for the treatment … pathway inhibitor (such as abiraterone [Zytiga], enzalutamide [Xtandi … approval provides a chemotherapy-free option for … in advanced prostate cancer. REFERENCES 1. FDA grants regular …